Cover Image, Volume 34, Issue 9.
Cover image, volume 34, issue 9.
J Comput Chem. 2013 Apr 5; 34(9): i-ii
The rapid development of drug resistance in microbes, the toxicity, and side effects of existing anti-infectious drugs are factors stimulating the effort directed toward a new generation of antibiotics. On page 790, Nikola Minovski, Andrej Perdih, Marjana Novic, and Tom Solmajer demonstrate how carefully validated in silico models using the recently determined structures of M. tuberculosis-DNA gyrase apoprotein and topoisomerase II-DNA-6-fluoroquinolones complexes are proficiently used for defining the drugs’ binding pockets and the subsequent design of a series of novel inhibitors of DNA gyrase from the class of substituted 6-fluoroquinolones (shown on the cover). HubMed – drug
Therapeutic Links between Alzheimer’s Disease and Brain Cancer: Drug Discovery Consequences.
ChemMedChem. 2013 Feb 26;
Kraus JL
It was recently reported that female survivors of breast cancer have a lower risk of Alzheimer’s disease (AD). This observation led to the hypothesis that there is a link between cancer and AD. This Viewpoint provides an analysis of the consequences of this hypothesis, not only from the perspective of drug discovery for new treatments, but above all, the awareness that any AD chemotherapy will require drug administration over longer periods of time before any cognitive effects are observed. Because such drugs will probably act as neuroprotective agents, slowing the progression of AD rather than curing it, they should be prescribed as soon as the first AD symptoms are detected. After a general survey of anticancer drugs that have potential therapeutic value for AD chemotherapy, new drugs that could affect specific signal transduction pathways known to be activated by anticancer drugs are presented, with the unfolding protein response pathway being one of the most relevant biological targets for new AD chemotherapeutic agents. HubMed – drug
Optimal duration of dual-antiplatelet therapy following drug-eluting stent implantation: a meta-analysis.
J Clin Pharmacol. 2013 Mar; 53(3): 345-51
Zhang T, Shen L, Hu L, He B
Optimal duration of dual-antiplatelet therapy (DAPT) following drug-eluting stent (DES) implantation remains uncertain. The aim of this study was to perform a meta-analysis of trials evaluating the effect of DAPT duration on long-term clinical outcomes after DES implantation. The authors searched OvidMEDLINE, EMBASE, and the Cochrane Library for both randomized controlled trials and nonrandomized studies that evaluated DAPT duration on long-term clinical outcomes after DES implantation. The end point was the cumulative incidence of the composite of all-cause death and nonfatal myocardial infarction (MI) at maximum follow-up. Quantitative analysis was performed to estimate the pooled hazard ratios (HRs) for the effect of DAPT duration. The pooled effect of DAPT discontinuation before 6 months significantly increased risk of death and nonfatal MI (HR, 1.46; 95% confidence interval, 1.18-1.80), but DAPT beyond 12 months did not reduce the incidence of the composite end point compared with drug discontinuation at 12 months (HR, 0.91; 95% confidence interval, 0.75-1.10). In conclusion, the current evidence suggests that 6 to 12 months of DAPT may be optimal after DES implantation. HubMed – drug